U.S. Biotech Stocks Shift to Pancreatic Cancer Electromagnetic Therapy, Market Cap Increases by 360 Billion Won in a Day

On April 4, shares of Novocure Ltd. (NASDAQ: NVCR) soared 11.39%, closing at $17.99 on the New York Nasdaq. Heavy trading pushed its market capitalization to about $2.1 billion (roughly KRW 2.8 trillion), adding approximately $270 million (KRW 360 billion) in a single day.

In its Q1 2026 earnings released at the end of April, Novocure reported revenue of $174.06 million and a loss per share of $0.62. The company raised its full-year revenue guidance to $690 million–$710 million, fueling growth expectations. In February, its Optune Pax wearable electric-therapy device for locally advanced pancreatic cancer received FDA approval, triggering a one-day stock jump of over 30% and spotlighting the revaluation potential from expanding indications.

Headquartered in Vevey, Switzerland, Novocure is a biotech firm specializing in oncology. Its Tumor Treating Fields (TTFields) technology uses electric fields to disrupt cancer cell division, and the company is extending approvals to brain tumors, lung cancer, and pancreatic cancer. Supported by clinical data showing extended survival when combined with standard chemotherapy, TTFields is gaining insurance coverage in the U.S., Japan, and other markets. Future regulatory changes and reimbursement policies are viewed as key drivers of the stock price.